The National Institutes of Health reports that obesity affects more than 42 percent of U.S. adults — a condition directly linked to elevated risk for type 2 diabetes mellitus, cardiovascular disease, hypertension, and chronic kidney disease. Among the medications now available for clinically meaningful weight loss, GLP-1 receptor agonists — specifically semaglutide — have produced results that were largely unavailable to primary care patients a decade ago.
Yet the most common practical question from patients evaluating semaglutide is not whether it works. The clinical evidence answers that. The question is how the dosing works: what the starting dose is, how long the titration schedule takes, what the maintenance dose of 2.4 mg actually means, and what happens if progress stalls before reaching it. This guide covers every stage of the GLP-1 semaglutide dosage schedule for weight loss — with the clinical rationale behind each phase.
Core Primary Care physicians across Houston, Sugar Land, Katy, and Needville, TX provide physician-supervised weight management using GLP-1 medications. The information here reflects FDA prescribing information, published clinical trial data, and consensus from recognized medical authorities including the NIH, Mayo Clinic, and the New England Journal of Medicine.
| Quick Clinical AnswerSemaglutide for weight loss (Wegovy) starts at 0.25 mg subcutaneously once weekly. The dose escalates every 4 weeks — through 0.5 mg, 1.0 mg, and 1.7 mg — reaching a maintenance dose of 2.4 mg weekly at approximately week 17. The full titration schedule takes 16-20 weeks. This gradual escalation is clinically required: it manages gastrointestinal side effects while allowing steady-state drug levels to establish. The dosing schedule must be supervised by a physician — self-adjusting the dose carries real safety risks. |
What Is a GLP-1 Medication and How Does Semaglutide Work?
GLP-1 stands for glucagon-like peptide-1 — a naturally occurring gut hormone released after eating. It signals the brain to reduce appetite, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. A glucagon-like peptide-1 receptor agonist mimics this hormone artificially, binding to the same receptor with a longer duration of action than the native hormone.
Semaglutide — developed by Novo Nordisk — is a GLP-1 receptor agonist with a chemical structure modified to resist rapid enzymatic breakdown. This modification extends its half-life to approximately one week, making once-weekly injection feasible. When administered subcutaneously, semaglutide reaches the GLP-1 receptors in both the hypothalamus (appetite regulation) and the GI tract (gastric emptying), producing sustained reductions in calorie intake without requiring active willpower to resist hunger.
Semaglutide is available in three FDA-approved formulations, each with a distinct dosage range and clinical indication: Wegovy (2.4 mg subcutaneous, weight management), Ozempic (up to 2 mg subcutaneous, type 2 diabetes mellitus and cardiovascular risk), and Rybelsus (oral tablet form, 14 mg daily, type 2 diabetes mellitus). Only Wegovy carries FDA approval specifically for chronic weight management in adults with obesity or overweight.
The Complete Semaglutide Dosage Schedule for Weight Loss
The Wegovy dosing schedule is a structured titration protocol that increases the dose in defined increments over approximately 16-20 weeks. The schedule is not flexible by patient preference — it is designed around GI tolerability and the pharmacokinetic behavior of the drug.
Starting Dose: 0.25 mg Weekly (Weeks 1-4)
The starting dose of semaglutide is 0.25 mg once weekly for the first four weeks. This is not a therapeutic dose for weight reduction. The dose at 0.25 exists solely to establish GI tolerance — giving the gut time to adjust to the GLP-1 mechanism before a meaningful therapeutic dose is introduced.
Nausea at this stage is common but typically mild. Patients should not expect significant weight loss during weeks 1-4. The clinical value of this phase is tolerability, not weight reduction.
First Escalation: 0.5 mg Weekly (Weeks 5-8)
Doses of 0.5 mg mark the first meaningful therapeutic step. At this dose, appetite suppression becomes more noticeable for many patients, and early weight reduction may begin — though the degree varies considerably between individuals. Every 4 weeks, the dose escalates, provided the current dose is being tolerated without severe GI events.
If nausea or vomiting is significant at 0.5 mg, the physician may hold the dose for an additional 4 weeks before continuing escalation. Forcing an increase through severe GI side effects does not improve long-term outcomes and often leads patients to discontinue treatment.
Second Escalation: 1.0 mg Weekly (Weeks 9-12)
The 1.0 mg dose is the standard maintenance range for Ozempic in patients with type 2 diabetes mellitus who do not require further escalation. For Wegovy patients following the weight management titration path, the dose of 1.0 mg is an intermediate step. Clinical trial data from semaglutide at the 1 mg dose (T2D studies) showed approximately 6-8% body weight reduction compared to placebo — lower than the 15% achieved at 2.4 mg, but clinically meaningful for many patients.
Third Escalation: 1.7 mg Weekly (Weeks 13-16)
The 1.7 mg dose is specific to the Wegovy weight management path and does not appear in the Ozempic T2D prescribing schedule. This intermediate step reduces the incremental jump from 1.0 mg to the 2.4 mg maintenance dose — making the final escalation more tolerable. By weeks 13-16, most patients have been on semaglutide treatment for approximately three months. Meaningful weight reduction is typically established at this stage.
Maintenance Dose: 2.4 mg Weekly (Week 17 Onward)
The maintenance dose of 2.4 mg weekly is the FDA-approved target for chronic weight management with Wegovy. Average weight loss at this dose in the pivotal STEP 1 trial — published in the New England Journal of Medicine — was approximately 15% of initial body weight over 68 weeks, compared to 2.4% in the placebo group. This represented average weight loss exceeding what was achievable with any previously approved obesity medication.
A 2025 phase 3b trial from UT Southwestern Medical Center examined higher doses of semaglutide above 2.4 mg and found increased weight loss and metabolic benefits, though using semaglutide at doses above the approved maximum is not current standard prescribing practice. For patients already at the maintenance dose where weight loss has plateaued, dietary reassessment and increased physical activity are the first clinical interventions — not exceeding approved dosage thresholds without physician guidance from a specialized program.
DOSING SCHEDULE TABLE:
| Weeks | Wegovy Dose | Ozempic Dose | Clinical Purpose |
| Weeks 1-4 | 0.25 mg/week | 0.25 mg/week | Starting dose — tolerance establishment, not therapeutic |
| Weeks 5-8 | 0.5 mg/week | 0.5 mg/week | First escalation; early appetite reduction begins |
| Weeks 9-12 | 1.0 mg/week | 1.0 mg/week | T2D maintenance range; meaningful weight reduction |
| Weeks 13-16 | 1.7 mg/week | Maintain 1-2 mg | Wegovy-specific intermediate step before max dose |
| Week 17+ | 2.4 mg/week | Max 2 mg (T2D) | Wegovy maintenance dose — weight management target |
Note: Escalation pace may be slowed based on tolerability at each stage. Physician discretion applies throughout.
Semaglutide Formulations: Wegovy, Ozempic, and Rybelsus Compared
Because semaglutide appears under three brand names with different indications and dosage ranges, patients frequently encounter confusion about which formulation applies to weight loss versus diabetes management.
| Feature | Wegovy | Ozempic | Rybelsus |
| Indication | Chronic weight mgmt | Type 2 diabetes + CV | Type 2 diabetes |
| Route | Subcutaneous injection | Subcutaneous injection | Oral tablet form (mg daily) |
| Max approved dose | 2.4 mg weekly | 2 mg weekly | 14 mg daily |
| Starting dose | 0.25 mg/week | 0.25 mg/week | 3 mg/day |
| Avg. weight loss | ~15% body weight | ~6-8% body weight | ~4-5% body weight |
| Manufactured by | Novo Nordisk | Novo Nordisk | Novo Nordisk |
Only Wegovy is FDA-approved for chronic weight management in adults with obesity. Ozempic carries FDA approval for type 2 diabetes mellitus and cardiovascular risk reduction — some physicians prescribe it off-label for weight loss, but the approved maximum dose (2 mg) is lower than Wegovy’s 2.4 mg. Rybelsus is the only oral tablet form of semaglutide and is approved for type 2 diabetes mellitus only — it is not an appropriate weight management substitution for Wegovy.
Why the Titration Schedule Exists: The Clinical Mechanism
The escalation structure is not administrative caution — it reflects the pharmacology of the glucagon-like peptide-1 receptor agonist mechanism. Activating GLP-1 receptors in the GI tract slows gastric emptying, which directly causes nausea, early satiety, and occasional vomiting during early treatment and dose increases.
At steady state — where once-weekly dosing maintains stable plasma drug concentrations — the acute GI receptor stimulation diminishes. The body’s GI sensitivity to the drug’s mechanism downregulates over weeks. This is why gastrointestinal side effects are most intense during dose escalation and why they typically improve significantly once a dose is held stable.
Increasing the dose before this adaptation occurs resets the process, producing a return of nausea and GI discomfort at each increment. The 4-week intervals between dose increases — and the 1.7 mg intermediate step before reaching 2.4 mg — are specifically designed to manage this biological response.
How to Administer the Semaglutide Injection
Both Wegovy and Ozempic are delivered via subcutaneous injection — under the skin, not intramuscularly. Appropriate injection sites include the abdomen (at least 2 inches from the navel), the front of the thigh, or the upper arm. The injection site should be rotated weekly to avoid tissue irritation.
Each dose comes in a pre-filled pen device with a concealed needle. The pen is placed against the skin, the button is pressed, and the injection completes within a few seconds. Patients should be trained by their prescribing physician or clinical staff before self-administering. If injection technique concerns exist, a clinical staff member can demonstrate the process during a follow-up visit.
The injection is given once weekly — on the same day each week. If a dose is missed: take it as soon as possible if the next scheduled dose is more than 2 days away. If fewer than 2 days remain until the next dose, skip the missed dose and resume the regular weekly schedule. Never take two doses in the same week to compensate for a missed injection. If uncertain about how to manage a missed dose during active escalation, contact your physician before taking the next dose.
Dose Adjustments: When a Physician May Change Your Dosing Schedule
Dose Hold for GI Intolerance
If gastrointestinal side effects at any escalation step are severe — persistent vomiting, significant dehydration, or inability to tolerate food — the physician may recommend holding the current dose for an additional 4 weeks rather than increasing. This is not a clinical failure. Tolerating the medication is more important than advancing the titration schedule on time.
When Weight Loss Has Plateaued
If weight loss has plateaued before reaching the maintenance dose and GI tolerability is good, the physician may recommend proceeding to the next dose level. For patients already at 2.4 mg where weight loss has plateaued, dose escalation beyond the approved maximum is not appropriate outside a clinical trial. The clinical response in this situation typically involves re-evaluating dietary patterns, assessing medication adherence, reviewing other contributing medications, and considering whether adding structured behavioral support improves outcomes.
Dose Adjustments for Comorbidities
Patients with chronic kidney disease require closer monitoring during semaglutide treatment. GI-related dehydration from nausea and vomiting increases the risk of acute kidney injury — not from the medication directly, but from fluid losses. Dosage adjustments are not typically required for mild-to-moderate renal impairment, but the prescribing physician must weigh risks carefully and monitor renal function.
Patients with type 2 diabetes mellitus who are also using insulin or sulfonylureas require monitoring for hypoglycemia as GLP-1 therapy improves glycemic control. The physician may reduce insulin or sulfonylurea doses as semaglutide treatment progresses — this is a proactive management step, not a sign that semaglutide is not working.
Dosing Changes Based on Medical History
Certain conditions make semaglutide contraindicated regardless of dose: personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, and pregnancy. Medical history review is required before any dose of semaglutide is prescribed. Never begin or adjust a GLP-1 medication without physician evaluation.
Common Side Effects and How the Dosing Schedule Reduces Them
The common side effects of semaglutide treatment at every dose level are predominantly gastrointestinal. Common side effects include:
- Nausea — most frequent, most intense in the first 2-4 weeks after each dose increase
- Vomiting — more common at higher doses; persistent vomiting should be reported to the physician
- Diarrhea — typically mild; improves with continued use at stable dose
- Constipation — frequent as appetite decreases and food intake drops; increased fluid intake often helps
- Abdominal discomfort, bloating, or early satiety
GI side effects are most pronounced during dose escalation and typically diminish significantly once a dose is held stable and the body reaches pharmacokinetic steady state. The gradual titration schedule exists specifically to reduce the risk of severe early GI events — not as a formality, but as a clinically necessary design feature.
Practical strategies: eat smaller, slower meals during escalation weeks; avoid high-fat meals, which amplify GI stimulation; stay well-hydrated; schedule injections on a consistent day that works with your tolerance pattern. If nausea is worst in the 24-48 hours post-injection, timing the injection for days when that discomfort is manageable can improve adherence.
Serious adverse events requiring immediate physician contact include: pancreatitis (sudden, severe abdominal pain radiating to the back), gallbladder disease (right upper quadrant pain), severe or persistent vomiting causing dehydration, and any significant change in vision (relevant in patients with type 2 diabetes).
Who Qualifies for GLP-1 Semaglutide Treatment for Weight Loss?
Wegovy is FDA-approved for adults with obesity (BMI 30 or above) or for patients with overweight or obesity (BMI 27 or above) with at least one weight-related comorbidity — including type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease — as an adjunct to a reduced-calorie diet and increased physical activity.
It is not approved for cosmetic weight reduction in patients who fall outside these criteria. A physician evaluation — including medical history, current medications, metabolic labs, and BMI confirmation — is required before any dose is prescribed.
Contraindications include personal or family history of medullary thyroid carcinoma or MEN2, current or planned pregnancy, and prior serious hypersensitivity reaction to semaglutide. Patients with active pancreatitis should not use semaglutide.
Semaglutide vs. Tirzepatide Dosage: Key Differences
Tirzepatide (Zepbound for weight loss; Mounjaro for type 2 diabetes mellitus) is a dual GLP-1 and GIP receptor agonist that starts at 2.5 mg weekly and escalates to a maximum of 15 mg weekly — a substantially different dosage range from semaglutide. The two medications are not interchangeable, should not be combined, and have distinct average weight loss profiles based on clinical trials.
For a full clinical comparison of both medications — including average weight loss results, side effect profiles, cardiovascular data, and which patient profiles suit each option — see the Core Primary Care guide: Semaglutide vs. Tirzepatide for Weight Loss: Which Is Right for You?.
When to Talk to a Physician About GLP-1 Dosage and Weight Management
A physician consultation is appropriate if:
- You are evaluating GLP-1 medications for weight management and want to confirm you meet the clinical criteria and understand the full dosing schedule before starting
- You are experiencing significant GI side effects at your current dose and are unsure whether to hold or advance to the next level
- Weight loss has plateaued before reaching the maintenance dose, or has stalled at 2.4 mg despite sustained adherence
- You are managing type 2 diabetes mellitus alongside obesity and need to understand how GLP-1 dosage interacts with your existing diabetes medications
- You have questions about switching GLP-1 medications — from semaglutide to tirzepatide or vice versa — and how the dose conversion works in practice
Core Primary Care physicians provide supervised weight management evaluation and ongoing GLP-1 dosage oversight across all four Texas locations.
Weight Loss Programs at Core Primary Care
This article is part of the Core Primary Care weight loss content library. Use the links below to explore location-specific weight loss programs and medication service pages:
Weight Loss by Location: Houston TX | Sugar Land TX | Katy TX | Needville TX
Medication Service Pages: Semaglutide for Weight Loss | Tirzepatide for Weight Loss | GLP-1 Medications Overview
Related Article: Semaglutide vs. Tirzepatide for Weight Loss: Which Is Right for You?
Developer note: Confirm all internal URL paths are live and indexed in Astro CMS before publishing. Update /services/weight-loss/* paths if URL structure differs from above.
Frequently Asked Questions
What is the starting dose of semaglutide for weight loss?
The starting dose is 0.25 mg subcutaneously once weekly for the first four weeks. This is a tolerance-building dose, not a therapeutic dose — it does not produce significant weight reduction on its own. Weight loss becomes more pronounced as the dose escalates toward the maintenance dose of 2.4 mg.
How long does the semaglutide titration schedule take?
The full titration schedule from starting dose to maintenance dose takes approximately 16-20 weeks: 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16), then 2.4 mg from week 17 onward. If the pace is slowed due to GI side effects, the timeline extends accordingly.
Can I take a higher dose than 2.4 mg for more weight loss?
The FDA-approved maximum dose of Wegovy is 2.4 mg weekly. Doses above this are not within current approved prescribing for weight management. Some clinical trials are examining higher doses and have shown additional weight reduction, but this is research-stage data and not yet standard practice. If weight loss has plateaued at the maintenance dose, discuss dietary, behavioral, and clinical options with your physician rather than pursuing unapproved dose escalation.
What is the difference between Wegovy and Ozempic dose?
Both contain semaglutide. Wegovy reaches a maximum dose of 2.4 mg weekly and is approved for chronic weight management. Ozempic reaches a maximum dose of 2 mg weekly and is approved for type 2 diabetes mellitus and cardiovascular risk reduction. Both follow similar early titration schedules but diverge at higher doses. They should not be used simultaneously.
How is semaglutide dosage different from tirzepatide?
Tirzepatide (Zepbound) starts at 2.5 mg weekly and escalates to 15 mg weekly — a substantially higher numerical range than semaglutide’s 0.25 to 2.4 mg. However, the dose numbers are not comparable directly because the medications have different molecular weights and receptor targets. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1 and GIP receptor agonist. Always follow the prescribed titration schedule for the specific medication you are using.
What should I do if I miss a dose?
If more than 2 days remain before your next scheduled dose, take the missed dose as soon as possible. If fewer than 2 days remain, skip the missed dose and resume your regular weekly schedule. Never take two doses in the same week. Contact your physician if you miss multiple doses or if you are in an active escalation phase and unsure how to proceed.
Will GI side effects improve once I reach the maintenance dose?
For most patients, yes. GI side effects are most intense during dose escalation — particularly in the 24-48 hours following each dose increase. Once the maintenance dose is held stable and the body reaches pharmacokinetic steady state, nausea and other GI side effects typically diminish significantly. Some patients find the 2.4 mg maintenance dose more tolerable than an intermediate escalation step because the body has had months to adapt.
Key Takeaways
- The GLP-1 semaglutide dosage schedule for weight loss follows a structured 16-20 week titration: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, increasing every 4 weeks.
- The starting dose of 0.25 mg is a tolerance-building step, not a therapeutic dose. Significant weight reduction builds through the escalation stages.
- The maintenance dose of 2.4 mg weekly (Wegovy) is the FDA-approved maximum for chronic weight management. Average weight loss in clinical trials was approximately 15% of body weight.
- GI side effects — nausea, diarrhea, constipation — are most intense during dose escalation and typically improve at steady state. The gradual titration schedule exists specifically to reduce these effects.
- Wegovy, Ozempic, and Rybelsus all contain semaglutide but have different approved indications, dosage ranges, and delivery methods. Only Wegovy is approved for weight management.
- Dose adjustments — whether to hold, escalate, or modify — must be managed by the prescribing physician based on individual tolerability and clinical response.
- Core Primary Care in Houston, Sugar Land, Katy, and Needville TX provides physician-supervised GLP-1 weight management evaluation and ongoing dosing oversight.
| Start Your Medical Weight Loss Evaluation at Core Primary CareIf you are considering semaglutide or another GLP-1 medication for weight management, physician supervision is clinically essential — not optional. Core Primary Care provides supervised medical weight loss evaluation and GLP-1 dosage management across Houston, Sugar Land, Katy, and Needville, TX. Schedule a consultation to confirm whether you meet clinical criteria and to receive a fully individualized dosing plan.Book at your nearest location: Houston | Sugar Land | Katy | Needville |